These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8058603)

  • 41. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration.
    Phipps PR; Gonda I
    Chest; 1990 Jun; 97(6):1327-32. PubMed ID: 2347217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) Respirator Solution.
    MacNeish CF; Meisner D; Thibert R; Kelemen S; Vadas EB; Coates AL
    Chest; 1997 Jan; 111(1):204-8. PubMed ID: 8996018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aerosolization potential of cyclodextrins--influence of the operating conditions.
    Le VN; Leterme P; Gayot A; Flament MP
    PDA J Pharm Sci Technol; 2006; 60(5):314-22. PubMed ID: 17089700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis.
    Spencer DA
    Thorax; 1997 Apr; 52 Suppl 2(Suppl 2):S89-91. PubMed ID: 9155860
    [No Abstract]   [Full Text] [Related]  

  • 45. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization.
    Nasr M; Najlah M; D'Emanuele A; Elhissi A
    Int J Pharm; 2014 Jan; 461(1-2):242-50. PubMed ID: 24275446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nebulized hypertonic saline and recombinant human DNase in the treatment of pulmonary atelectasis in newborns.
    Dilmen U; Karagol BS; Oguz SS
    Pediatr Int; 2011 Jun; 53(3):328-31. PubMed ID: 20831650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.
    Conway SP; Watson A
    Thorax; 1997 Apr; 52 Suppl 2(Suppl 2):S64-8. PubMed ID: 9155855
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome.
    Desai M; Weller PH; Spencer DA
    Pediatr Pulmonol; 1995 Nov; 20(5):307-8. PubMed ID: 8903903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal evaluation of compressor/nebulizer performance.
    Awad S; Williams DK; Berlinski A
    Respir Care; 2014 Jul; 59(7):1053-61. PubMed ID: 24149670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RhDNase I aerosol deposition and related factors in cystic fibrosis.
    Diot P; Palmer LB; Smaldone A; DeCelie-Germana J; Grimson R; Smaldone GC
    Am J Respir Crit Care Med; 1997 Nov; 156(5):1662-8. PubMed ID: 9372691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of commercial jet nebulizers.
    Loffert DT; Ikle D; Nelson HS
    Chest; 1994 Dec; 106(6):1788-92. PubMed ID: 7988201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New pharmacological approaches: rhDNase].
    Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
    Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of three commercial ultrasonic nebulizers.
    Katial RK; Reisner C; Buchmeier A; Bartelson BB; Nelson HS
    Ann Allergy Asthma Immunol; 2000 Feb; 84(2):255-61. PubMed ID: 10719784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaporation of aqueous aerosols produced by jet nebulizers: effects on particle size and concentration of solution in the droplets.
    Phipps PR; Gonda I
    J Aerosol Med; 1994; 7(3):239-58. PubMed ID: 10150482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Vitro Comparison of a Vibrating Mesh Nebulizer Operating in Inspiratory Synchronized and Continuous Nebulization Modes During Noninvasive Ventilation.
    Michotte JB; Staderini E; Le Pennec D; Dugernier J; Rusu R; Roeseler J; Vecellio L; Liistro G; Reychler G
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):328-36. PubMed ID: 27310926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
    N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization.
    Ip AY; Arakawa T; Silvers H; Ransone CM; Niven RW
    J Pharm Sci; 1995 Oct; 84(10):1210-4. PubMed ID: 8801336
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physical properties of aerosols produced by several jet- and ultrasonic nebulizers.
    Sterk PJ; Plomp A; van de Vate JF; Quanjer PH
    Bull Eur Physiopathol Respir; 1984; 20(1):65-72. PubMed ID: 6704568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
    Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
    Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aerosol delivery during spontaneous breathing with different types of nebulizers- in vitro/ex vivo models evaluation.
    Lin HL; Fang TP; Cho HS; Wan GH; Hsieh MJ; Fink JB
    Pulm Pharmacol Ther; 2018 Feb; 48():225-231. PubMed ID: 29277689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.